∆ |
Change |
↑ |
Increase |
↓ |
Decrease |
ABP |
Ambulatory blood pressure |
ABPM |
Ambulatory blood pressure monitoring |
ACE |
Angiotensin-converting enzyme |
ADE |
Adverse drug event |
AE |
Adverse event |
ARBs |
Angiotensin receptor blockers |
ARF |
Acute renal failure |
AST |
Aspartate transaminase |
BID |
Twice daily |
BIW |
Twice weekly |
BP |
Blood pressure |
BSA |
Body surface area |
CABG |
Coronary artery bypass graft |
CBC |
Complete blood count |
CCr |
Creatinine clearance |
CESDS |
Center for Epidemiologic Studies Depression Scale |
CFU-E |
Erythroid colony-forming units |
CHF |
Congestive heart failure |
CHOIR |
Correction of Hemoglobin and Outcomes in Renal Insufficiency |
CHr |
Content of hemoglobin in reticulocytes |
CI |
Confidence interval |
CKD |
Chronic kidney disease |
CMV |
Cytomegalovirus |
CPG |
Clinical practice guideline |
CPR |
Clinical practice recommendation |
CREATE |
Cardiovascular Risk Reduction by Early Anemia Treatment With Epoetin Beta Trial |
CRI |
Corrected reticulocyte index |
CV |
Cardiovascular |
CVA |
Cerebrovascular accident |
CVD |
Cardiovascular disease |
D/C |
Discontinuation |
DBP |
Diastolic blood pressure |
DNA |
Deoxyribonucleic acid |
DOQI |
Dialysis Outcomes Quality Initiative |
EBPG |
European Best Practices Guideline |
eGFR |
Estimated glomerular filtration rate |
ERI |
Erythropoietin resistance index |
ERT |
Evidence Review Team |
ESA |
Erythropoiesis-stimulating agent |
ESRD |
End-stage renal disease |
FACIT |
Functional Assessment of Chronic Illness Therapy |
FDA |
Food and Drug Administration |
GFR |
Glomerular filtration rate |
GI |
Gastrointestinal |
Hb |
Hemoglobin |
Hct |
Hematocrit |
HD |
Hemodialysis |
HD-CKD |
Hemodialysis-dependent chronic kidney disease |
HDF |
Hemodiafiltration |
HPS |
Hemophagocytic syndrome |
HTN |
Hypertension |
HU |
Hydroxyurea |
HUI |
Health Utilities Index |
HUS |
Hemolytic uremic syndrome |
IHD |
Ischemic heart disease |
IM |
Intramuscular |
IU |
International Unit |
IV |
Intravenous |
KDIGO |
Kidney Disease: Improving Global Outcomes |
KDOQI |
Kidney Disease Outcomes Quality Initiative |
KDQ |
Kidney Disease Questionnaire |
KDQOL |
Kidney Disease Quality of Life |
KEEP |
Kidney Early Evaluation Program |
KLS |
Kidney Learning System |
KPS |
Karnofsky Performance Scale |
LV |
Left ventricular |
LVD |
Left ventricular dilation |
LVEDd |
Left ventricular end-diastolic diameter |
LVH |
Left ventricular hypertrophy |
LVMI |
Left ventricular mass index |
LVVI |
Left ventricular volume index |
MAP |
Mean arterial blood pressure |
MCH |
Mean corpuscular hemoglobin |
MCHC |
Mean corpuscular hemoglobin concentration |
MCV |
Mean corpuscular volume |
MDRD4 |
Modification of Diet in Renal Disease |
MI |
Myocardial infarction |
MR |
Mitral regurgitation |
N, n |
Number of subjects |
N/A |
Not applicable |
NAPRTCS |
North American Pediatric Renal Transplant Cooperative Study |
nd |
Not documented |
ND-CKD |
Non–dialysis-dependent chronic kidney disease |
NHANES |
National Health and Nutrition and Examination Survey |
NKF |
National Kidney Foundation |
NOS |
Not otherwise specified |
NS |
Not significant |
OR |
Odds ratio |
PD |
Peritoneal dialysis |
PD-CKD |
Peritoneal dialysis–dependent chronic kidney disease |
PHRBC |
Percent hypochromic red blood cells |
PHRC |
Percent hypochromic red cells |
PO |
Oral |
PRCA |
Pure red cell aplasia |
Pt |
Patient |
PTA |
Posttransplantation anemia |
QoAL |
Quality of American Life |
QOL |
Quality of life |
QOW |
Every other week |
RCT |
Randomized controlled trial |
rHuEPO |
Recombinant human erythropoietin |
RQoLP |
Renal Quality of Life Profile |
RR |
Relative risk |
SAE |
Severe adverse event |
SBP |
Systolic blood pressure |
SC |
Subcutaneous |
SCD |
Sudden cardiac death |
SCr |
Serum creatinine |
SF-36 |
36-Item Medical Outcomes Study Short-Form Health Survey |
SIP |
Sickness Impact Profile |
SQUID |
Superconducting quantum interference device |
TDS |
Total daily supplement |
TID |
Thrice daily |
TIW |
Thrice weekly |
TRESAM |
Transplant European Survey on Anemia Management |
TSAT |
Transferrin saturation |
TTO |
Time trade-off |
TTP |
Thrombotic thrombocytopenic purpura |
Tx-ND-CKD |
Non–dialysis-dependent kidney transplant recipient population |
U |
Unit |
URR |
Urea reduction ratio |
USFDA |
United States Food and Drug Administration |
USRDS |
United States Renal Data System |
vs |
Versus |
WHO |
World Health Organization |
ZPP |
Zinc protoporphyrin |